Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

Presentation

Interpreting JAK Inhibitor Safety Signals in Context

Description

The speaker explains that JAK inhibitors have generated both excitement and confusion because their strong efficacy is matched by ongoing concerns about safety, especially after the oral surveillance study. They emphasize that safety signals must be interpreted in context: clinical trials and safety studies often enroll older, sicker, higher-risk patients and may use different comparators, follow-up durations, and event adjudication methods, so results may not generalize to the average patient. Oral surveillance, which studied an older rheumatoid arthritis population with many cardiovascular risk factors and no placebo arm, found higher relative risks with tofacitinib, especially at higher doses, leading to updated boxed warnings. However, the absolute risks were low, and the excess risk appeared concentrated in the highest-risk patients, particularly older smokers. In contrast, many real-world studies and dermatology trials have not reproduced clear increases in MACE, VTE, malignancy, or serious infection for more selective JAK inhibitors, though shingles remains a class effect and can be dose-related. The speaker argues that baseline disease risk, patient factors like age, smoking, prior clots, cardiovascular disease, obesity, and steroid use, and drug selectivity all shape observed outcomes. Their counseling approach is to use shared decision-making centered on the “three Cs” — cardiac events, clots, and cancers — while also recommending shingles vaccination and minimizing systemic steroid exposure. Overall, they conclude that JAK inhibitor risk is real but often overstated without considering population, comparator, dose, and baseline risk.

View more

Conclusions

The safety signal seen in ORAL Surveillance likely reflects a worst-case, risk-enriched rheumatoid arthritis population rather than a uniform class effect across all patients.
Absolute rates of MACE, VTE, malignancy, and serious infection were generally low even when relative risks appeared elevated in high-risk groups.
Baseline patient factors such as age, smoking history, prior VTE, cardiovascular disease, obesity, and steroid use were the main drivers of adverse-event risk.
Real-world studies have not consistently reproduced the excess cardiovascular or cancer risks reported in ORAL Surveillance.
Dermatology populations such as atopic dermatitis, alopecia areata, vitiligo, and hidradenitis suppurativa appear to have different baseline risk profiles than rheumatoid arthritis.
Across dermatology randomized trials, JAK inhibitors have not shown a clear increase in MACE, VTE, or malignancy compared with controls, though follow-up is often short.
Herpes zoster is the most consistent class safety signal for JAK inhibitors and appears dose-related, especially in some populations.
More selective, second-generation JAK inhibitors generally seem to have fewer off-target effects than older pan-JAK agents, which may influence safety.
Risk assessment should focus on the patient’s baseline comorbidities and disease context rather than the boxed warning alone.
Shared decision-making should lead with disease risk, contextualize the warning, and then individualize counseling using the patient’s cardiac, clotting, and cancer history.

Ytterberg SR et al. N Engl J Med. 2022.
Bunick CG et al. J Invest Dermatol. 2025.
Merola JF et al., J Am Acad Dermatol. 2024;90:935–944.
Solitano V et al., JAMA Network Open, 2025.
Roubille C et al. Rheumatology. 2019;58:14-116.
Lin CMA et al. Mediter. J Rheumatol. 2020;31(Suppl 1):100–104.